# Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

> **NCT02269592** · — · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 10000 (estimated)

## Conditions studied

- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Myelodysplastic Syndromes
- Hematological Malignancies
- B-cell Malignancy, Low-grade
- Myelodysplastic Syndrome With Low-grade Lesions
- IgG Monoclonal Gammopathy of Uncertain Significance
- Smoldering Multiple Myeloma
- Waldenstrom Macroglobulinemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02269592
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2014-08
- **Primary completion:** 2027-12
- **Final completion:** 2030-09
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269592, "Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT02269592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*